Novo Nordisk Faces a Triple Test: Generics, Q1 Results, and a Pipeline Showcase

Novo Nordisk enters a critical period with Q1 earnings, a Canadian Ozempic generic launch, and obesity conference data, as shares remain 41% below year-ago levels.

Novo Nordisk enters May with an unusually packed calendar that could determine whether its battered shares have finally found a floor. The Danish drugmaker is juggling the expiry of a share buyback tranche, first-quarter earnings due Wednesday, and a major medical conference where it will unveil data from over 50 studies — all while its stock languishes roughly 41% below year-ago levels.

The Canadian Generic Threat Lands at an Awkward Moment

Just days before Novo Nordisk reports earnings, Health Canada authorized the first generic version of Ozempic from Dr. Reddy’s Laboratories. The copycat product is approved exclusively for type 2 diabetes, with regulators explicitly excluding the weight-loss drug Wegovy from the authorization. Canada represents the world’s second-largest market for semaglutide, and Novo Nordisk’s patent protection there expired in early January.

More competitors are lining up. Sandoz and Teva have also filed applications, with Sandoz targeting a June launch. Market observers expect significant price erosion: a single generic typically pushes prices to 75% of the original, while three competitors often drive them down to 35%. BMO Capital Markets analyst Evan Seigerman views Canada as a critical test case for how the original drug holds up against generics, though he doesn’t see an immediate global threat — the crucial US patents don’t expire until the early 2030s.

Q1 Earnings Under the Microscope

Novo Nordisk will release its first-quarter results before the market opens on Wednesday, May 6. This marks the first earnings report since the company issued a downbeat full-year forecast. Analysts expect earnings per share of $0.87, with the market pricing in a roughly 7% swing in either direction. The consensus points to a profit decline of about 5% from the prior year.

Investors will scrutinize prescription trends for Wegovy, particularly the oral version, which is seen as a key indicator of future market positioning. The relative strength index currently sits at 23, signaling deeply oversold conditions. The stock has stabilized somewhat, gaining nearly 11% over the past month to trade around €35.17, but it remains down roughly 21% year-to-date — far below its 52-week high.

Buyback Program Wraps Up

The current tranche of Novo Nordisk’s share buyback program, targeting B-shares worth up to DKK 3.8 billion, runs from February 4 to May 4. As of April 24, the company had repurchased nearly 13.4 million B-shares at an average price of DKK 256.48. Whether a new tranche will be announced immediately remains to be seen, but clarity should emerge in the coming days.

Istanbul Conference as a Pipeline Showcase

From May 12 to 15, Novo Nordisk will present data from 52 abstracts at the European Congress on Obesity in Istanbul. The program extends beyond weight reduction to include cardiovascular health and physical function. Central to the presentation is the STEP-UP study, testing a 7.2 mg dose of semaglutide, along with results from the REDEFINE program evaluating CagriSema — a combination of semaglutide and the long-acting amylin analog cagrilintide.

New Frontiers: Orthopedics and AI

Less noticed but strategically significant, Novo Nordisk has launched a phase 3 trial called AMAZE 5, testing the experimental drug NNC0487-0111 in overweight patients with knee osteoarthritis. The once-weekly injection aims to reduce weight and alleviate pain, marking the company’s entry into orthopedics.

In April, the company also announced a partnership with OpenAI to accelerate drug discovery by analyzing complex datasets more efficiently. Pilot programs will run in research, manufacturing, and sales, with full integration targeted by the end of 2026. Financial terms were not disclosed.

Pipeline Progress Offers a Counterweight

Beyond the competitive pressures, Novo Nordisk’s pipeline for rare diseases is showing promise. The experimental drug etavopivat reduced painful crises in sickle cell disease by 27% in a phase 3 trial, nearly doubling the time to the first event compared with placebo. The company plans to file for approval in the second half of 2026.

What Analysts Are Watching

Kepler Capital maintains a "Hold" rating on the stock, citing persistent headwinds. The analyst consensus sees fair value at DKK 307.70, about 14% above the current price of DKK 263.50. But the Q1 report on May 6 will provide the first hard data on how deeply pricing pressure is cutting into margins — and whether the Canadian generic launch is just the beginning of a broader erosion.